Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Up to 144 New Stock Opportunities Make This Sector Ripe for Profits
In doing so, I learned two very important things.
The first is that the success of an individual medical technology (medtech) or biotechnology (biotech) company isn’t directly tied to the greater cyclical forces that often affect other stocks.
The second thing I learned is that over the course of time, the medtech and biotech industries offer investors the most chances at triple-digit gains in any given month. This is because medtech and biotech stocks are catalyst-driven.
Let me show you a few examples.
A Sector That Is Always Ripe for Profits
Search jobs 11-May-2021 Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer Data from the first positive Phase III study of a cancer immunotherapy in early, resected lung cancer Studies in personalized healthcare exploring tumor agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualized treatment plans New data, and drug combination strategies for the treatment of lymphoma from the largest hematology portfolio in industry
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held June 4-8, 2021. A tot
Triple-Negative Breast Cancer Market Research Report 2018-2030: Analysis of Domain, Therapies, Epidemiology and Key Companies in 7MM by DelveInsight
iCrowd Newswire
DelveInsight s
The report also offers comprehensive insights into Triple Negative Breast Cancer market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing Triple Negative Breast Cancer clinical trials, collaboration in the space, and key pharmaceutical companies actively pushing the growth of Triple-Negative Breast Cancer market size forward in the 7MM [US, EU5(Germany, France, the United Kingdom, Spain, and Italy) and Japan].
Some of the key highlights from the
USD 438 Million in 2017.
The
largest market size of TNBC, in comparison to the other